This article is more than 5 years old. Information may no longer be current.

Botox shows greater efficacy vs. Xeomin at 1:1 dose ratio for reduction of upper face wrinkles

Although Botox and Xeomin each significantly reduced individual and combined wrinkles at similar time points, Botox had statistically greater efficacy when compared with Xeomin at an identical dosage, according to findings from a split-face, randomized, double-blind study.

Forty-five patients ranging in age from 26 years to 82 years (mean age: 52.9 years) were enrolled in the study. The sides of the patients’ faces were randomly assigned to treatment with 22.5 units of Botox (onabotulinumtoxinA, Allergan) or 22.5 units of Xeomin (incobotulinumtoxinA, Merz) at baseline. Researchers reconstituted one 100 MU vial each of onabotulinumtoxinA and incobotulinumtoxinA using 2 mL of 0.9% sterile saline solution. All patients underwent the same injection pattern, and dosages were compared with those from other studies based on location.

Follow-up occurred at 3 days, 2 weeks, 3 months and 4 months following the initial treatment, during which, the researchers assessed the efficacy and safety of the treatments and took photographs. They also documented any treatment-related adverse events to occur.

Overall, the researchers found no difference for individual or combined static wrinkle reduction between the toxins. However, onabotulinumtoxinA offered statistically better efficacy comparatively over time, maintaining a higher performance over incobotulinumtoxinA at all follow-up time points.

A higher dose ratio of incobotulinumtoxinA may be necessary to have the same effect as onabotulinumtoxinA, according to the researchers. - by Abigail Sutton

Disclosures: Yeilding reports no relevant financial disclosures. Please see the full study for a list of all other authors’ relevant financial disclosures.